Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Netherlands Pharmaceuticals And Healthcare
Industry SWOT — 6
Netherlands Political
SWOT — 7
Netherlands Economic SWOT — 8
Netherlands Political Industry SWOT — Error! Bookmark not
defined.
Pharmaceutical Business Environment
Ratings — 9
Table: Western Europe - Regional
Pharmaceutical Business Environment Ratings for Q309 — 9
Limits to Potential Returns — 10
Risks to Realisation Of
Returns — 10
The Netherlands - Market
Summary — 11
Regulatory Regime — 12
Recent EU Regulatory Developments — 12
Intellectual
Property Developments — 14
Pricing and
Reimbursement — 15
Industry
Developments — 17
Recent Public Health
Developments — 18
Healthcare
Sector — 18
Healthcare Spending — 19
Healthcare Insurance — 20
Table: Key Points – Dutch
Health Insurance Act, January 1 2006 — 21
Recent
Healthcare Insurance Developments — 22
Pharmaceuticals
Sector — 23
Recent Domestic Companies’
Activities — 25
Recent Foreign Companies’
Activities — 26
Wholesale and Retail
Sector — 28
Recent Wholesale and Retail Sector
Developments — 29
Research and Development
Sector — 29
Medical Devices
Industry — 31
Recent Medical Devices Industry
Developments — 32
Industry Forecast
Scenario — 33
Overall Market
Forecast — 33
Table: Netherlands - Drug Market Indicators,
Historical Data and Forecasts — 34
Key Growth Factors
– Industry — 35
Table: Netherlands - Health
Expenditure Indicators, Historical Data and Forecasts — 36
Key Growth Factors – Macroeconomic — 37
Table:
Netherlands – Economic Activity, 2006 –
2013 — 39
Prescription Market
Forecast — 40
Table: Netherlands – Prescription
Market Indicators, Historical Data and Forecasts (EURmn unless otherwise
stated) — 41
Patented Market
Forecast — 42
Table: Netherlands - Patented Drug Market
Indicators, Historical Data and Forecasts — 42
Generics
Market Forecast — 43
Table: Netherlands - Generics Market
Indicators, Historical Data and Forecasts — 44
OTC Market
Forecast — 45
Table: Netherlands - OTC Drugs Market
Indicators, Historical Data and Forecasts (EURmn unless otherwise
stated) — 47
Pharmaceutical Trade
Forecasts — 48
Table: Netherlands - Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$bn) — 49
Other Healthcare Data — 49
Table: Netherlands –
Other Health Indicators, Historical Data And
Forecasts — 50
Key Risks to BMI’s Forecast
Scenario — 50
Competitive
Landscape — 51
Company Profiles — 52
Leading Multinational Manufacturers — 52
Merck &
Co — 52
Pfizer — 54
GlaxoSmithKline
(GSK) — 56
Sanofi-Aventis — 58
Novartis — 59
Indigenous
Manufacturers — 61
Akzo Nobel — 61
DSM — 64
Qiagen — 67
Pharming
Group — 68
Crucell — 69
Country
Snapshot: Netherlands Demographic Data — 71
Section 1:
Population — 71
Table: Demographic Indicators,
2005-2030 — 71
Table: Rural/Urban Breakdown,
2005-2030 — 72
Section 2: Education And
Healthcare — 72
Table: Education,
2002-2005 — 72
Table: Vital Statistics,
2005-2030 — 72
Section 3: Labour Market And Spending
Power — 73
Table: Employment Indicators,
2000-2005 — 73
Table: Consumer Expenditure, 2000-2012
(US$) — 73
Table: Average Annual Wages,
2000-2012 — 74
BMI Forecast
Modelling — 75
How We Generate Our Pharmaceutical Industry
Forecasts — 75
Pharmaceutical Business Environment Ratings
Methodology — 76
Ratings Overview — 76
Table: Pharmaceutical Business Environment Indicators — 77
Weighting — 78
Table: Weighting Of
Components — 78
Sources — 78
| 
View Cart
